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Cilostazol reduces restenosis after carotid artery
stenting
Tomoji Takigawa, MD,a Yuji Matsumaru, MD,a Mikito Hayakawa, MD,a Shigeru Nemoto, MD,b and
Akira Matsumura, MD,c Tokyo, Togichi, and Ibaraki, Japan
Background: Although carotid artery stenting (CAS) has been proposed as an alternative to carotid endarterectomy in
cerebral revascularization, restenosis remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has
vasodilatory effects and inhibits smooth muscle cell proliferation. We investigated whether cilostazol reduces restenosis
after CAS.
Methods: A database of 113 consecutive CAS procedures between April 2002 and December 2007 was assessed
retrospectively. All patients received aspirin (100 mg/d) and another antiplatelet drug such as cilostazol (200 mg/d),
ticlopidine (200 mg/d), or clopidogrel (75 mg/d) at least 3 days before CAS. Two antiplatelet drugs were continued for
2 to 3 months after CAS and reduced to one thereafter. Patients were evaluated at 3 and 6 months and at 6-month
intervals thereafter with duplex ultrasound (DUS) imaging. Angiography was used for confirmation when stenosis was
suspected as >50% with DUS imaging.
Results: We were able to monitor 97 patients for a 12-month period. The overall combined rate of stroke, myocardial
infarction, and death was 3.1% at 30 days and 4.1% at 1 year. In-stent recurrent stenosis was documented in 11 patients
(11%); in 10 patients (9.7%), this occurred <12 months of CAS. In-stent restenosis was significantly reduced in the
cilostazol () group (0% vs 15.7% [11 of 70], P .03). Patient characteristics were similar between the cilostazol () and
cilostazol (–) groups.
Conclusions: Although this study was retrospective and nonrandomized, the results suggest that cilostazol administration
improves long-termpatency after CASdue to its inhibitory effect on smoothmuscle cell growth. (J Vasc Surg 2010;51:51-6.)Carotid artery stenting (CAS) is being used widely to
treat severe carotid obstructive disease and is now accepted
as a less invasive technique that provides an alternative for
some patients, particularly those with significant comor-
bidities.1-5 Although distal embolism decreased with the
use of the embolization protection device (EPD), up to
10% of patients develop 50% stenosis as determined by
angiography or carotid duplex ultrasound (DUS) scanning,
and this problem is not yet solved.3,6-8 The rate approaches
20% in some patient subgroups, such as women and the
elderly.7
These series of studies placed aspirin, ticlopidine, or
clopidogrel as the current standard of antiplatelet drugs.
Cilostazol, a cyclic adenosine monophosphate phosphodi-
esterase inhibitor, has multiple actions, including vasodila-
tion and inhibition of platelet aggregation.9-11 Cilostazol is
widely used as an antiplatelet drug in Japan. Several small
trials reported that cilostazol use after endovascular treat-
ment for peripheral artery and coronary artery diseases has a
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doi:10.1016/j.jvs.2009.08.040low rate of in-stent restenosis.12-22 However, it is not
known whether a preventive effect of cilostazol on resteno-
sis is similarly recognized after CAS. Accordingly, the
present study was undertaken to determine whether cilosta-
zol is effective in preventing restenosis after CAS compared
with other antiplatelet drugs.
METHODS
Study design and patient sample. A retrospective
study was conducted of patients who had undergone CAS
between April 2002 and December 2007. Carotid DUS
scans performed before the stenting procedure docu-
mented high-grade carotid stenosis in all patients. High-
risk patients for carotid endarterectomy (CEA) with symp-
tomatic carotid stenosis of50% and asymptomatic carotid
stenosis of80%were considered for the stenting protocol.
Procedural indications, clinical, laboratory, antiplatelet
drugs, techniques, treatment outcomes, and the postoper-
ative course were analyzed.
Eligibility for CAS was further determined on the basis
of criteria established at a consensus conference,23 includ-
ing:
● recurrent stenosis after previous CEA;
● contralateral carotid occlusion;
● primary lesions in patients with significant medical
comorbid conditions, such as coronary artery disease
requiring angioplasty or bypass grafting that has not or
cannot be revascularized, history of congestive heart
failure, current ejection fraction of 30% (stage III or
IV of the New York Heart Association classification),
steroid-dependent chronic obstructive pulmonary dis-
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ond of 30%;
● a primary lesion anatomically inaccessible at surgery,
such as high carotid bifurcation (C2 level); and
● a primary lesion in a patient with previous ipsilateral
cervical radiation therapy.
During this period, 106 patients underwent 113 CAS
procedures, and we were able to monitor 97 patients for 12
months. These included 83 men and 14 women with a
mean age of 69.9 7.2 years. Of these, 61 patients (62.9%)
had symptomatic stenosis and 36 (37.1%) had asymptom-
atic lesions. Indications for CAS included recurrent stenosis
after previous CEA in 5 (5.1%), high-risk cardiac comor-
bidity in 26 (26.8%), high-risk pulmonary comorbidity in 1
(1.0%), high carotid bifurcation in 30 (30.9%), and previ-
ous ipsilateral cervical radiation therapy in 8 (8.2%). Clini-
cal characteristics are presented in Table I.
CAS protocol. A neurologist independent from the
study examined all patients before each procedure to deter-
mine neurologic status. DUS scanning was also performed
in all cases. Patients treated electively received aspirin (100
mg/d) and another antiplatelet agent such as clopidogrel
(75 mg/d), ticlopidine (200 mg/d), or cilostazol (200
mg/d) for at least 3 days before the intervention. Patients
electively received aspirin and thienopyridine (ticlopidine
or clopidogrel). Clopidogrel was approved in Japan by the
Pharmaceutical Affairs Law after December 2006, so pa-




Patients, total 97 (100)
Age, y 69.6  7.2
Male sex 83 (85.6)
Type of lesion
Asymptomatic carotid stenosis 36 (37.1)
Symptomatic carotid stenosis 61 (62.9)
Stroke 38 (39.2)
Transient ischemic attack 16 (16.5)
Amaurosis fugax 7 (7.2)
Severity of stenosis, % 82.9  9.5
Comorbidities
Coronary artery disease 32 (33.0)






Renal insufficiency 7 (7.2)
Peripheral artery disease 8 (8.2)
CAS indications
High-risk cardiac comorbidity 26 (26.8)
High carotid bifurcation 30 (30.9)
High-risk pulmonary comorbidity 1 (1.0)
History of neck irradiation 8 (8.2)
Stenosis after CEA 5 (5.1)
CAS,Carotid artery stenting;CEA, carotid endarterectomy;COPD, chronic
obstructive pulmonary disease; SD, standard deviation.tients received ticlopidine before then, and clopidogrel wasadded after December 2006. Patients with peripheral artery
disease or coronary artery disease received cilostazol or
thienopyridine, or both, before CAS. This combination of
antiplatelet drugs was continued from the protocol for
cardiovascular medicine.
Standard monitoring techniques were used during
CAS, including intra-arterial pressure monitoring, oxime-
try, and continuous electrocardiography. During the pro-
cedure, the patient’s neurologic status was continuously
monitored by verbal command.
Standard retrograde access was achieved through the
common femoral artery under local anesthesia with 1%
lidocaine. An 8F vascular sheath was inserted. Heparin was
administered to achieve an activated clotting time of300
seconds.
An 8F guiding catheter was navigated into the common
carotid artery. Carotid angiogram and intracranial injec-
tions were performed. A 0.018-inch guidewire system with
EPD was then manipulated to cross the internal carotid
lesion. For patients with high-grade stenosis that was nearly
occluded or with thrombosis, procedures were performed
using the reversed-flow system.
After the activation of the EPD system, a coaxial angio-
plasty balloon was used to predilate the carotid lesion if
necessary. Next, a self-expanding carotid stent was de-
ployed across the internal carotid stenosis. Postdilation was
performed if necessary. On completion, ipsilateral cervical
and intracranial carotid angiography was performed to
assess technical success and to exclude distal cerebral em-
bolization.
Patients were monitored in an intensive care unit over-
night and were discharged 3 or 4 days later. A clinical
examination and DUS scanning were performed before
discharge to confirm stent patency and position. One anti-
platelet drug was prescribed to be taken for life and another
to be terminated after 2 or 3 months. Life-long aspirin
therapy was prescribed. In patients with peripheral artery
disease or coronary artery disease, cilostazol or thienopyri-
dine, or both, was added before CAS. This combination of
antiplatelet drugs was continued from the protocol for
cardiovascular medicine. After CAS, this combination was
continued for life.
Follow-up protocol and criteria for restenosis
assessment. All patients were scheduled for follow-up at
the hospital’s outpatient clinic at 1, 3, 6, 9, and 12 months
after the procedure and every 6 months thereafter. During
these routine postoperative visits, the surgeon and the
independent neurologist examined each patient, and ca-
rotid DUS scans were performed at 3 and 6 months and at
6-month intervals thereafter.
The velocity criteria used to evaluate carotid artery
stenosis were modifications of the Japanese Academy of
Neurosonology Guidelines for Neurosonology and were
validated in our hospital. Peak systolic velocity150 cm/s
correlated with 50% stenosis.24 In addition, luminal re-
ductions on grayscale images and color flow disturbances
were further evaluated. In-stent restenosis identified by
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and stenosis was measured geometrically on the basis of the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET) criteria.25 When 50% restenosis was
recognized, carotid angioplasty and possible stenting were
subsequently performed.
Statistical analysis. Clinical variables that may be as-
sociated with restenosis after CAS were analyzed. Contin-
uous data are shown as mean  standard deviation (SD).
The unpaired t test was used to compare continuous vari-
ables between the groups. The 2 test or Fisher’s exact test
was used to compare ratios. Statistical significance was
defined as a P  .05.
RESULTS
CAS outcomes at 30 days and 1 year. All lesions
were accessed, and the procedures were performed success-
fully, for a technical success rate of 100%. Mean stenosis
treated was 82.9%  9.5%, and the mean residual stenosis
after treatment was 5.2%  0.5%. Wallstents (Boston Sci-
entific, Natick, Mass) were deployed in 71 procedures
(73.2%), Precise (Cordis, Miami, Fla) in 8 (8.2%), Protage
(eV3, Plymouth, Minn) in 2 (2.1%), Xpert (Abbott Vascu-
lar, Redwood City, Calif) in 1 (1.0%), and SMARTeR stent
(Cordis) in 15 (15.5%). All stenting procedures were per-
formed with EPDs, including the PercuSurge Guardw-
ire device (Medtronic, Minneapolis Minn) in 82 (84.5%),
AngioGuard XP (Cordis) in 7 (7.2%), and a reversed-flow
system in 7 (7.2%).
The overall 30-day stroke, myocardial infarction, and
death rate was 3.1% (n  3). Each of the three strokes was
minor (2 ipsilateral minor strokes and 1 contralateral
stroke). Postoperative DUS scanning was performed 1
week after CAS. No in-stent restenosis, carotid dissections,
or thromboses were documented. During the 1-year follow-
up, one patient sustained a myocardial infarction. The
overall 1-year outcome for stroke, myocardial infarction,
and death was 4.1%.
Long-term follow-up and in-stent restenosis. Nine
patients were lost to follow-up, which was amean of 28.6
13.3 months (range, 12-67 months). In-stent restenosis,
confirmed by DUS scanning and angiography, was de-
tected in 11 of 97 carotid arteries (11.3%) within a mean of
8.9  3.0 months (range, 5-16 months). Mean restenosis
was 55.5%  7.2%, and mean peak systolic velocity was
200.8  75.1 cm/s. All patients with recurrent stenosis
were asymptomatic. Patients were a mean age of 69.3 
16.2 years, and there were 10 men and one woman. A
comparison of patient characteristics, clinical symptoms,
CAS indications, CAS devices, and CAS technique among
the patients with in-stent restenosis and without in-stent
restenosis found no significant difference (Table II).
Two patients did not want repeat treatment and were
monitored with serial clinical evaluation and DUS scanning
at 3- to 6-month intervals. Nine of 11 patients underwent
endovascular reintervention, consisting of repeat balloon
angioplasty in five and repeat angioplasty and secondary
stenting in four. Technical success was achieved in allpatients, and the mean carotid artery stenosis decreased
from 54.6% to 11% after reintervention. No procedurally
related complications were noted after in-stent restenosis






P(n  86) (n  11)
Age, mean  SD, y 69.7  7.2 69.3  7.9 .93
Male sex, % 84.8 90.1 .93
Type of lesion, %
Asymptomatic carotid
stenosis 38.4 27.3 .70
Symptomatic carotid
stenosis 61.6 72.7 .70
Stroke 38.4 45.5 .90
Transient ischemic
attack 16.2 18.1 .79
Amaurosis fugax 7.0 9.1 .72
Severity of stenosis,
mean  SD, % 82.5  9.9 85.8  5.2 .10
Comorbidities, %
Coronary artery disease 32.5 36.4 .93
History of myocardial
infarction 18.6 18.2 .71
Smoking 70.9 81.8 .69
Hypertension 82.6 63.6 .28
Diabetes 30.2 27.3 .88
Chronic obstructive
pulmonary disease 1.2 0 .22
Hypercholesterolemia 51.2 45.5 .97
Renal insufficiency 8.1 0 .72
Peripheral artery




comorbidity 26.7 27.3 .75
High carotid
bifurcation 30.2 36.4 .95
High-risk pulmonary
comorbidity 1.2 0 .22
History of neck
irradiation 8.1 9.1 .64
Stenosis after carotid
endarterectomy 5.8 0 .92
Stents, %
Wallstent 74.4 63.6 .69
Precise 8.1 9.1 .64
SMARTeR 14.0 27.3 .48
Xpert 1.2 0 .22
Protage 2.3 0 .54
Embolization protectin
device, %
PercuSurge Guardwire 83.7 90.9 .86
AngioGuard 7.0 9.1 .72
Navi balloon 1.2 0 .22
Reversed-flow system 8.1 0 .72
Preballoon dilatation, % 97.7 100 .54
Postballoon dilatation, % 80.2 72.7 .85
Residual stenosis post-op,
mean  SD, % 4.8  5.2 8.9  8.0 .21
ISR, In-stent restenosis; SD, standard deviation.intervention. All patients who underwent reintervention
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periods of 20.6 months.
Antiplatelet therapy after CAS and in-stent
restenosis. Antiplatelet drugs that were continued for 1
year after CAS are presented in Table III. The combina-
tions of antiplatelet agents were aspirin, 28; ticlopidine,
3; clopidogrel, 10; cilostazol, 1; aspirin and ticlopidine,
23; aspirin and clopidogrel, 6; aspirin and cilostazol, 19;
cilostazol and clopidogrel, 3; aspirin and ticlopidine and
cilostazol, 1; and aspirin and clopidogrel and cilostazol,
3.
No significant differences were noted in overall 30-day
and 1-year stroke, myocardial infarction, and death among
patients in each drug group. Patients in the cilostazol ()
group had 0% incidences of restenosis compared with
15.7% for patients without cilostazol (P  .03). The reste-
nosis rate was 25.9% in patients who took ticlopidine
compared with 5.7% in patients without ticlopidine (P 
.01). Patient, lesion characteristics, and CAS technique did
not differ between the cilostazol () and cilostazol (–)
groups. Use of additional drugs was similar between the
groups, except that ticlopidine was used more frequently in
the cilostazol (–) group than in the cilostazol () group.
DISCUSSION
The incidence of postprocedural in-stent restenosis is
1% to 50% in published reports.1,3,26-28 The reported
rate of in-stent restenosis depends on the definition of
recurrent stenosis, duration of follow-up, and the meth-
ods of diagnosis. Although most of these reports were
based on short follow-up periods, several authors more
recently presented findings after periods of longer fol-
low-up. Setacci et al29 reported a 3.6% incidence of
high-grade restenosis (80%) during a 21-month fol-
low-up period with more than 372 carotid stents. Simi-
larly, Chakhtoura et al26 reported an 8% high-grade
restenosis rate during their 18-month follow-up of 50
Table III. Antiplatelet drugs used in 97 patients after









(n  3) (n  4) (n  11)
Aspirin (), No. (%) 80 2 (2.5) 3 (3.8) 8 (10.0)
Aspirin (–), No. (%) 17 1 (5.9) 1 (5.9) 3 (17.6)
Cilostazol (), No. (%) 27 1 (3.7) 1 (3.7) 0 (0)a
Cilostazol (–), No. (%) 70 2 (2.9) 3 (4.3) 11 (15.7)
Ticlopidine (), No. (%) 27 0 (0) 1 (3.7) 7 (25.9)b
Ticlopidine (–), No. (%) 70 3 (4.3) 3 (4.3) 4 (5.7)
Clopidogrel (), No. (%) 22 2 (9.1) 2 (9.1) 3 (13.6)
Clopidogrel (–), No. (%) 75 1 (1.3) 2 (2.7) 8 (10.7)
MI, Myocardial infarction.
aP  .03; bP  .01.CAS procedures. Our study, likewise, demonstrated an11.3%moderate-grade (50%) in-stent restenosis rate dur-
ing a mean 28.6-month follow-up period.
Cilostazol, a phosphodiesterase 3 inhibitor, has anti-
platelet action, vasodilatory effects, and inhibits smooth
muscle cell proliferation.10,11,30,31 Cilostazol reportedly
increases the cyclic adenosine monophosphate phosphodi-
esterase level in vascular smooth muscle cells, resulting in
upregulation of the antioncogenes p53 and p21 and hepa-
tocyte growth factor.32 Because the increase in p53 protein
blocks cell cycle progression and induces apoptosis in vas-
cular smooth muscle cells, these mechanisms have an anti-
proliferative effect.33 Furthermore, hepatocyte growth fac-
tor stimulates re-endothelialization after vascular injury,
inhibits abnormal vascular smooth muscle cell growth, and
improves endothelial function.34
Because neointimal hyperplasia is a major cause of recur-
rent stenosis after CAS, these actions may possibly explain the
beneficial effect of cilostazol on reducing the in-stent resteno-
sis rate. Cilostazol also inhibits P-selectin-mediated leukocyte
activation, platelet-leukocyte interaction, and subsequent
Mac-I-mediated leukocyte activation.35 Because inhibition of
these actions is thought to reduce neointimal thickening after
vascular injury, this mechanism may also be important in the
reduction of restenosis after CAS.
Earlier studies have indicated that cilostazol improves
symptoms and increases walking distance in patients with
peripheral artery disease with intermittent claudication.12
Recent studies have shown that cilostazol reduces resteno-
sis and target lesion revascularization after percutaneous
transluminal angioplasty in patients with peripheral artery
disease.13-15 Consequently, cilostazol is a class 1 drug for
patients with peripheral artery disease according to Ameri-
can Heart Association guidelines.36
Several studies have also shown that cilostazol has the
potential to reduce restenosis compared with aspirin after
balloon angioplasty, stent implantation, and directional
coronary atherectomy.16-20 Douglas et al12 reported that
cilostazol was effective on restenosis after coronary artery
stenting compared with placebo. Tanabe et al21 reported
on the effect of cilostazol on restenosis after coronary
angioplasty and stenting compared with coronary artery
stenting with ticlopidine.
In the study presented here, cilostazol was as effective
as other antiplatelet drugs in preventing periprocedual and
1-year complications after CAS, as evidenced by the lack of
any significant differences in vascular events observed at the
30-day and 1-year follow-up visits. Furthermore, cilostazol
was more effective in reducing restenosis after stent implan-
tation than the other antiplatelet drugs. The inhibitory
effect of cilostazol on restenosis may not be due to its
antiplatelet effects but is possibly due to its direct inhibition
of smooth muscle cell growth.
This study was a nonrandomized, retrospective at a
single-center trial, and there were few numbers. A large-
scale, prospective, multicenter study should be undertaken
to verify these preliminary conclusions.
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Cilostazol may have the potential to reduce the rate of
restenosis after CAS due to its inhibitory effect on smooth
muscle cell growth.
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